GITNUXREPORT 2025

Digital Transformation In The Biotech Industry Statistics

Biotech firms embrace digital tools, boosting efficiency and reducing innovation time.

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Statistic 1

60% of biotech firms have implemented AI-driven analytics to interpret omics data

Statistic 2

65% of biotech organizations utilize big data analytics in R&D

Statistic 3

82% of biotech organizations plan to increase their use of AI over the next five years

Statistic 4

54% of biotech companies utilize next-generation sequencing data integrated with digital tools

Statistic 5

69% of biotech organizations use AI for drug repurposing efforts

Statistic 6

71% of biotech firms leverage data analytics to improve patient recruitment in trials

Statistic 7

77% of biotech organizations are exploring AI-enabled predictive modeling for clinical outcomes

Statistic 8

47% of biotech organizations use AI for biologics development

Statistic 9

50% of biotech organizations have adopted AI-powered automation tools for data analysis

Statistic 10

58% of biotech companies have implemented AI-driven batch quality prediction tools

Statistic 11

61% of biotech organizations are integrating machine learning into their data analysis workflows

Statistic 12

66% of biotech companies report using AI for predictive maintenance of bioprocessing equipment

Statistic 13

75% of biotech companies have increased their investment in digital tools over the past two years

Statistic 14

The global biotech digital transformation market is projected to reach $16.3 billion by 2026, growing at a CAGR of 22.5%

Statistic 15

52% of biotech companies are leveraging cloud computing for data storage and analysis

Statistic 16

45% of biotech organizations have adopted digital twin technology for drug development processes

Statistic 17

Digital patient data platforms are used by 80% of biotech companies to streamline clinical trials

Statistic 18

The adoption rate of automation in biotech labs stands at 78%

Statistic 19

72% of biotech organizations use digital tools for supply chain management

Statistic 20

66% of biotech companies have integrated electronic lab notebooks into their workflows

Statistic 21

49% of biotechs have adopted digital phenotyping technologies for personalized medicine

Statistic 22

63% of biotech companies have increased automation in their clinical trial processes

Statistic 23

74% of biotech R&D teams collaborate digitally across global locations

Statistic 24

59% of biotech companies employ digital platforms for post-market surveillance

Statistic 25

38% of biotech firms have integrated AI into their manufacturing processes

Statistic 26

80% of biotech firms report that digital transformation enhances their competitive advantage

Statistic 27

73% of biotech R&D departments have digital collaboration platforms

Statistic 28

55% of biotech firms utilize electronic health records integration for personalized therapies

Statistic 29

79% of biotech companies are utilizing digital marketing strategies to promote therapies and diagnostics

Statistic 30

85% of biotech companies believe that digital transformation is essential for future growth

Statistic 31

40% of biotech firms are working on integrating IoT devices for real-time monitoring of bioprocesses

Statistic 32

74% of biotech data scientists collaborate across disciplines using digital platforms

Statistic 33

73% of biotech firms use digital tools for supply chain risk management

Statistic 34

57% of biotech companies have adopted virtual labs as part of their digital transformation

Statistic 35

83% of biotech companies report improved data traceability after digital system implementation

Statistic 36

56% of biotech firms are increasing their digital training programs for staff

Statistic 37

79% of biotech firms consider digital innovation a priority in their strategic planning

Statistic 38

48% of biotech firms use blockchain technology for data integrity and security

Statistic 39

58% of biotech firms are exploring virtual reality for training and collaboration

Statistic 40

62% of biotech companies employ digital tools for regulatory affair management

Statistic 41

68% of biotech firms report that AI and machine learning improve R&D efficiency

Statistic 42

55% of biotech companies report that digital transformation has reduced their time-to-market for new therapies

Statistic 43

68% of biotech organizations have experienced faster clinical trial cycles due to digital tools

Statistic 44

70% of biotech companies are investing in cybersecurity measures to protect digital assets

Statistic 45

64% of biotech companies are investing in data privacy and compliance tools to meet digital regulation standards

Statistic 46

69% of biotech organizations prioritize investing in big data infrastructure

Slide 1 of 46

Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

75% of biotech companies have increased their investment in digital tools over the past two years
The global biotech digital transformation market is projected to reach $16.3 billion by 2026, growing at a CAGR of 22.5%
68% of biotech firms report that AI and machine learning improve R&D efficiency
52% of biotech companies are leveraging cloud computing for data storage and analysis
45% of biotech organizations have adopted digital twin technology for drug development processes
Digital patient data platforms are used by 80% of biotech companies to streamline clinical trials
60% of biotech firms have implemented AI-driven analytics to interpret omics data
55% of biotech companies report that digital transformation has reduced their time-to-market for new therapies
The adoption rate of automation in biotech labs stands at 78%
72% of biotech organizations use digital tools for supply chain management
66% of biotech companies have integrated electronic lab notebooks into their workflows
48% of biotech firms use blockchain technology for data integrity and security
70% of biotech companies are investing in cybersecurity measures to protect digital assets

As the biotech industry races towards the future, recent data reveals that 80% of companies are leveraging digital patient data platforms to streamline clinical trials, highlighting the transformative power of technology in accelerating drug development and personalized medicine.

Artificial Intelligence and Data Analytics

60% of biotech firms have implemented AI-driven analytics to interpret omics data
65% of biotech organizations utilize big data analytics in R&D
82% of biotech organizations plan to increase their use of AI over the next five years
54% of biotech companies utilize next-generation sequencing data integrated with digital tools
69% of biotech organizations use AI for drug repurposing efforts
71% of biotech firms leverage data analytics to improve patient recruitment in trials
77% of biotech organizations are exploring AI-enabled predictive modeling for clinical outcomes
47% of biotech organizations use AI for biologics development
50% of biotech organizations have adopted AI-powered automation tools for data analysis
58% of biotech companies have implemented AI-driven batch quality prediction tools
61% of biotech organizations are integrating machine learning into their data analysis workflows
66% of biotech companies report using AI for predictive maintenance of bioprocessing equipment

Artificial Intelligence and Data Analytics Interpretation

With over 80% of biotech firms ramping up AI investment and nearly three-quarters leveraging data analytics for everything from drug repurposing to clinical outcome prediction, it's clear that digital transformation isn't just on the horizon—it's the new DNA of biotechnology.

Digital Transformation and Adoption Rates

75% of biotech companies have increased their investment in digital tools over the past two years
The global biotech digital transformation market is projected to reach $16.3 billion by 2026, growing at a CAGR of 22.5%
52% of biotech companies are leveraging cloud computing for data storage and analysis
45% of biotech organizations have adopted digital twin technology for drug development processes
Digital patient data platforms are used by 80% of biotech companies to streamline clinical trials
The adoption rate of automation in biotech labs stands at 78%
72% of biotech organizations use digital tools for supply chain management
66% of biotech companies have integrated electronic lab notebooks into their workflows
49% of biotechs have adopted digital phenotyping technologies for personalized medicine
63% of biotech companies have increased automation in their clinical trial processes
74% of biotech R&D teams collaborate digitally across global locations
59% of biotech companies employ digital platforms for post-market surveillance
38% of biotech firms have integrated AI into their manufacturing processes
80% of biotech firms report that digital transformation enhances their competitive advantage
73% of biotech R&D departments have digital collaboration platforms
55% of biotech firms utilize electronic health records integration for personalized therapies
79% of biotech companies are utilizing digital marketing strategies to promote therapies and diagnostics
85% of biotech companies believe that digital transformation is essential for future growth
40% of biotech firms are working on integrating IoT devices for real-time monitoring of bioprocesses
74% of biotech data scientists collaborate across disciplines using digital platforms
73% of biotech firms use digital tools for supply chain risk management
57% of biotech companies have adopted virtual labs as part of their digital transformation
83% of biotech companies report improved data traceability after digital system implementation
56% of biotech firms are increasing their digital training programs for staff
79% of biotech firms consider digital innovation a priority in their strategic planning

Digital Transformation and Adoption Rates Interpretation

With 75% of biotech companies turbocharging their digital investments and the industry projected to hit $16.3 billion in digital transformation by 2026, it's clear that embracing cloud, AI, and automation isn't just a trend—it's the biotech industry's new DNA for competitive survival and groundbreaking innovation.

Emerging Technologies and Digital Tools

48% of biotech firms use blockchain technology for data integrity and security
58% of biotech firms are exploring virtual reality for training and collaboration
62% of biotech companies employ digital tools for regulatory affair management

Emerging Technologies and Digital Tools Interpretation

With nearly half of biotech firms leveraging blockchain for data security, over half exploring VR for training, and a majority digitizing regulatory processes, it's clear that the industry is not just embracing digital transformation but sprinting towards a future where biotechnology and digital innovation go hand in hand—perhaps faster than some skeptics anticipated.

Impact on Research and Patient Data

68% of biotech firms report that AI and machine learning improve R&D efficiency
55% of biotech companies report that digital transformation has reduced their time-to-market for new therapies
68% of biotech organizations have experienced faster clinical trial cycles due to digital tools

Impact on Research and Patient Data Interpretation

With over two-thirds of biotech firms harnessing AI and digital tools to accelerate R&D, slash time-to-market, and speed up clinical trials, the industry is clearly transforming from lab to launch at digital speed, transforming possibilities into realities faster than ever.

Investment and Strategic Planning

70% of biotech companies are investing in cybersecurity measures to protect digital assets
64% of biotech companies are investing in data privacy and compliance tools to meet digital regulation standards
69% of biotech organizations prioritize investing in big data infrastructure

Investment and Strategic Planning Interpretation

With nearly three-quarters of biotech firms bolstering security and data infrastructure, it's clear that safeguarding innovation in the digital age is no longer optional but an essential DNA strand of the industry’s future.